VALIDATION OF THE RUSSIAN-LANGUAGE VERSION OF THE RAPID-3 QUESTIONNAIRE
https://doi.org/10.14412/1995-4484-2011-59
Abstract
Objective: to evaluate the psychometric properties of the Russian-language version of the routine assessment of patient index data (RAPID-3) questionnaire in patients with rheumatoid arthritis (RA).
Subjects and methods. The reliability, sensitivity, and validity of the RAPID-3 index were estimated in 100 patients with verified RA. Reliability assessment comprised the study of the reproducibility and internal consistency of the index. The reproducibility was assessed by the test-retest method; the internal consistency was estimated calculating the Cronbach-alpha coefficient; the sensitivity was determined comparing the RAPID-3 values with a response to treatment according to the ACR-50 criteria. Design validity was ascertained using correlation analysis with external criteria.
Results. Test-retest analysis in patients with unchanged health status failed to reveal statistically significant differences between the initial (15.17±5.57) and repeat (13.1±5.89) values of the RAPID-3 index; the Cronbach-alpha coefficient was 0.8. Improved health according to the ACR-50 criteria was correlated with better RAPID-3 values. Lower disease activity in accordance with the RAPID-3 index was more marked in patients who had achieved 50% improvement as shown by the ACR criteria. The posttreatment decline in the RAPID-3 index averaged 3.9±0.1 scores. In patients who had not achieved 50% improvement by the hospital discharge, the disease activity change was less pronounced (Δ RAPID-3 = 1.9±0.2 scores).
There were high correlations of RAPID-3 values with clinical parameters: the number of swollen joints (R=0.61) and tender joints (R = 0.46), combined DAS 28 indices (R=0.72), simple (R=0.60) and clinical (R=063) disease activity indices (SDAI and CDAI), inflammation activity index (IAI) (R=0.62), health assessment questionnaire (HAQ) (R=0.64), and quality of life questionnaire (EQ-5D) scores (R=0.52). Conclusion. The RAPID-3 index is a reliable, sensitive, and valid tool to evaluate inflammation activity and functional status in patients with RA
Subjects and methods. The reliability, sensitivity, and validity of the RAPID-3 index were estimated in 100 patients with verified RA. Reliability assessment comprised the study of the reproducibility and internal consistency of the index. The reproducibility was assessed by the test-retest method; the internal consistency was estimated calculating the Cronbach-alpha coefficient; the sensitivity was determined comparing the RAPID-3 values with a response to treatment according to the ACR-50 criteria. Design validity was ascertained using correlation analysis with external criteria.
Results. Test-retest analysis in patients with unchanged health status failed to reveal statistically significant differences between the initial (15.17±5.57) and repeat (13.1±5.89) values of the RAPID-3 index; the Cronbach-alpha coefficient was 0.8. Improved health according to the ACR-50 criteria was correlated with better RAPID-3 values. Lower disease activity in accordance with the RAPID-3 index was more marked in patients who had achieved 50% improvement as shown by the ACR criteria. The posttreatment decline in the RAPID-3 index averaged 3.9±0.1 scores. In patients who had not achieved 50% improvement by the hospital discharge, the disease activity change was less pronounced (Δ RAPID-3 = 1.9±0.2 scores).
There were high correlations of RAPID-3 values with clinical parameters: the number of swollen joints (R=0.61) and tender joints (R = 0.46), combined DAS 28 indices (R=0.72), simple (R=0.60) and clinical (R=063) disease activity indices (SDAI and CDAI), inflammation activity index (IAI) (R=0.62), health assessment questionnaire (HAQ) (R=0.64), and quality of life questionnaire (EQ-5D) scores (R=0.52). Conclusion. The RAPID-3 index is a reliable, sensitive, and valid tool to evaluate inflammation activity and functional status in patients with RA
References
1. <div><p>Smolen J., Aletaha D., Bijlsma J.W.J. et al. Treating RA to target: recommendation of an international task force. Ann Rheum Dis 2010;69:631-7.</p><p>Pincus T., Brooks R.H., Callahan L.F. Prediction of long-term mortality in patients with rheumatoid arthritis according to simple questionnaire and join count measures. Ann Intern Med 1994;120:20-34</p><p>Fries J.F., Spitz P.W., Kraines R.G., Holman H.R. Measurement of patient outcome in arthritis. Arthr Rheum 1980; 23:137-45.</p><p>Pincus T., Bergman M.J., Yazici Y. RAPID3 - An Index of Physical Function, Pain, and Global Status as «Vital Signs» to Improve Care for People with Chronic Rheumatic Diseases. Bull NYU Hospital Joint Dis 2009;67(2):211-25.</p><p>Pincus T., Swearingen C., Wolfe F. Toward a multidimensional health assessment questionnaire (MDHAQ): assessment of advanced activities of daily living and psychological status in the patient friendly health assessment questionnaire format. Arthr Rheum 1999;42:2220-30.</p><p>Meenan R.F., Gertman P.M., Mason J.H. Measuring helth status in arthritis the Artrithis Impact Measurement Scales. Arthr Rheum 1980;23:146-52</p><p>Pincus T., Amara I., Segurado O., Koch G. An index based on only patient reported outcome (PRO) measures, routine assessment of patient index data (RAPID3), distinguishes adalimumab from control at levels similar to disease activity score (DAS28) and clinical disease activity index (CDAI) [Abstract]. Ann Rheum Dis 2007;184:66.</p><p>Smolen Js., Breedveld F.C., Schiff M.H. et аl. A simplified disease activity index for rheumatoud artritis for use in clinical practice. Rheumatology (Oxford) 2003; 42:244 57.</p><p>Aletaha D., Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): A review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheum 2005;23(Suppl. 39):100-8.</p><p>Олюнин Ю.А., Балабанова Р.М. Определение активности ревматоидного артрита в клинической практике. Тер арх 2005;5:23-6.</p><p>Новик А.А., Ионова Т.И. Руководство по исследованию качества жизни в медицине. СПб.: Олма-Пресс, 2002;300 с.</p><p>Pincus T., Bergman M.J., Yazici Y. et al. An index of only patient reported outcome measures, routine assessment of patient index data 3 (RAPID3), in two abatacept clinical trials: similar results to disease activity score (DAS28) and other RAPID indices that include physician-reported measures. Rheumatology (Oxford) 2008; 47(3):345-9.</p><p>The EuroQol group. EuroQol - a new facility for the measurement of health related quality of life. Helth Policy 1990; 16:199-208</p></div><br />
Review
For citations:
Starkova A.S., Amirdzhanova V.N. VALIDATION OF THE RUSSIAN-LANGUAGE VERSION OF THE RAPID-3 QUESTIONNAIRE. Rheumatology Science and Practice. 2011;49(4):36-40. (In Russ.) https://doi.org/10.14412/1995-4484-2011-59
Views:
1141
Email this article 